TABLE I.
Characteristics of the studied cohorts
| Case-cohort set |
Subcohort |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ATBC (N=2,250) |
Finrisk (N=2,300) |
Northern Sweden (N=397) |
PRIME/ Belfast (N=331) |
PRIME/ France (N=335) |
ATBC (N=1,032) |
Finrisk (N=837) |
Northern Sweden (N=165) |
PRIME/ Belfast (N=144) |
PRIME/ France (N=163) |
|
| Men (%) | 2,250 (100.0) |
1,580 (68.7) |
259 (65.2) |
331 (100.0) |
335 (100.0) |
1,032 (100.0) |
618 (73.8) |
107 (64.8) |
144 (100.0) |
163 (100.0) |
| Mean age at baseline (SD) |
64.1 (8.3) |
57.9 (8.3) |
57.6 (8.3) |
55.4 (8.3) |
55.8 (8.3) |
64.3 (8.3) |
58.4 (8.3) |
56.6 (8.3) |
55.4 (8.3) |
56.1 (8.3) |
| MI at baseline (%) | 376 (16.7) |
428 (18.6) |
70 (17.6) |
35 (10.6) |
9 (2.7) |
103 (10.0) |
71 (8.5) |
8 (4.8) |
9 (6.2) |
3 (1.8) |
| Stroke at baseline (%) |
200 (8.9) |
250 (10.9) |
47 (11.8) |
2 (0.6) |
4 (1.2) |
45 (4.4) |
32 (3.8) |
4 (2.4) |
1 (0.7) |
1 (0.6) |
| Diabetes at baseline (%) | 170 (7.6) |
245 (10.7) |
36 (9.1) |
16 (4.8) |
31 (9.3) |
58 (5.6) |
62 (7.4) |
9 (5.5) |
6 (4.2) |
13 (8.0) |
| CHD during follow-up (%) |
564 (25.1) |
603 (26.2) |
52 (13.1) |
116 (35.0) |
101 (30.1) |
118 (11.4) |
86 (10.3) |
4 (2.4) |
10 (6.9) |
6 (3.7) |
| Stroke (CI) during follow-up (%) |
269 (12.0) |
229 (10.0) |
45 (11.3) |
11 (3.3) |
17 (5.1) |
63 (6.1) |
39 (4.7) |
7 (4.2) |
0 (0.0) |
0 (0.0) |
| Death during follow- up(%) |
962 (42.8) |
662 (28.8) |
105 (26.4) |
61 (18.4) |
61 (18.2) |
233 (22.6) |
97 (11.6) |
15 (9.1) |
6 (4.2) |
2 (1.2) |
| Mean HDL cholesterol (SD) |
1.15 (0.31) |
1.28 (0.36) |
1.30 (0.38) |
1.15 (0.33) |
1.23 (0.32) |
1.18 (0.31) |
1.31 (0.37) |
1.35 (0.39) |
1.17 (0.38) |
1.28 (0.30) |
| Mean non-HDL cholesterol (SD) |
4.83 (1.09) |
4.52 (1.11) |
5.30 (1.25) |
4.89 (1.10) |
4.49 (1.01) |
4.78 (1.10) |
4.52 (1.07) |
5.22 (1.29) |
4.83 (1.05) |
4.44 (0.99) |
| Mean BMI (SD) | 26.9 (4.2) |
28.1 (4.5) |
27.0 (4.1) |
26.4 (3.3) |
26.9 (3.7) |
26.8 (4.3) |
27.8 (4.2) |
26.5 (4.0) |
25.8 (3.3) |
26.9 (3.7) |
| Current daily smoker (%) |
1728 (76.8) |
588 (25.6) |
93 (23.4) |
97 (29.3) |
89 (26.6) |
794 (76.9) |
178 (21.3) |
34 (20.6) |
32 (22.2) |
31 (19.0) |
| Drug treatment for high cholesterol (%) |
NA | 184 (8.0) |
11 (2.8) |
6 (1.8) |
49 (14.6) |
NA | 39 (4.7) |
2 (1.2) |
4 (2.8) |
23 (14.1) |
| Drug treatment for high blood pressure (%) |
NA | 576 (25.0) |
85 (21.4) |
33 (10.0) |
79 (23.6) |
NA | 181 (21.6) |
22 (13.3) |
9 (6.2) |
27 (16.6) |
| Successful genotyping for all SNPs (%) |
2,219 (98.6) |
2,249 (97.8) |
394 (99.2) |
318 (96.1) |
314 (93.7) |
1,017 (98.5) |
815 (97.4) |
164 (99.4) |
138 (95.8) |
149 (91.4) |
The case-cohort set includes the subcohort and all case definitions (CHD, stroke and all deaths).